Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorHugh Taylor
About this trial
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Eligibility criteria
Qualifiers
Healthy, non pregnant females
ages ≥18 and ≤40 years old at time of enrollment
with either AS, AE, or RIF
For AS: surgical history of intrauterine trauma/infection, hypo/amenorrhea, intra-uterine adhesions
Disqualifiers
Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)
Endometriosis (diagnosed by previous surgery,)
Diminished ovarian reserve (AMH<1ng/ml or follicle stimulating hormone (FSH)>10)
History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly
Trial design
Treatments tested in this trial
- Plerixafor
Treatment groups
90 Participants
are divided into 1 treatment groupSponsors and collaborators
Hugh Taylor
Lead sponsor
Yale University
Sponsor institution
Source ClinicalTrials.gov